FDA 483 - Serum Institute of India Pvt. Ltd. - April 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Serum Institute of India Pvt. Ltd., a biological manufacturer in Manjari Bk., revealed significant deficiencies across multiple areas. Findings included poor documentation practices, issues with analytical methods and reference standards, deviations from approved manufacturing processes, and inadequate investigations and environmental monitoring in aseptic processing areas. These observations indicate a need for comprehensive improvements in quality systems and manufacturing controls.
ID · 5e9f3fa6-e4a7-41aa-bc15-bb9f16f43c46